Open Problems in Extracellular RNA Data Analysis: Insights From an ERCC Online Workshop
- PMID: 35047007
- PMCID: PMC8762274
- DOI: 10.3389/fgene.2021.778416
Open Problems in Extracellular RNA Data Analysis: Insights From an ERCC Online Workshop
Abstract
We now know RNA can survive the harsh environment of biofluids when encapsulated in vesicles or by associating with lipoproteins or RNA binding proteins. These extracellular RNA (exRNA) play a role in intercellular signaling, serve as biomarkers of disease, and form the basis of new strategies for disease treatment. The Extracellular RNA Communication Consortium (ERCC) hosted a two-day online workshop (April 19-20, 2021) on the unique challenges of exRNA data analysis. The goal was to foster an open dialog about best practices and discuss open problems in the field, focusing initially on small exRNA sequencing data. Video recordings of workshop presentations and discussions are available (https://exRNA.org/exRNAdata2021-videos/). There were three target audiences: experimentalists who generate exRNA sequencing data, computational and data scientists who work with those groups to analyze their data, and experimental and data scientists new to the field. Here we summarize issues explored during the workshop, including progress on an effort to develop an exRNA data analysis challenge to engage the community in solving some of these open problems.
Keywords: DREAM challenge; RNA sequencing; RNA-seq; batch variation; biomarker discovery; deconvolulion; extracellular RNA; tissue of origin.
Copyright © 2022 Alexander, Kitchen, Tosar, Roth, Mestdagh, Max, Rozowsky, Kaczor-Urbanowicz, Chang, Balaj, Losic, Van Nostrand, LaPlante, Mateescu, White, Yu, Milosavljevic, Stolovitzky and Spengler.
Conflict of interest statement
EV is co-founder, member of the Board of Directors, on the SAB, equity holder, and paid consultant for Eclipse BioInnovations. EV’s interests have been reviewed and approved by the Baylor College of Medicine in accordance with its conflict of interest policies. RS is a paid consultant for Lacerta Therapeutics. Author RY was employed by the company Aginome Scientific, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
